A pilot study to examine the efficacy and safety of escitalopram in doses up to 50 mg for the treatment of patients with Major Depressive Disorder (MDD). - Resistant Depression Study

CPS Research0 个研究点目标入组 60 人开始时间: 2008年6月18日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1.written informed consent will be obtained from each patient
•2.aged 18 to 65 inc
•3.suffering from MDD as defined by DSM IV
•4.have been taking citalopram in a dose of at least 20mg for at least six weeks
•5.an inadequate response -- defined as failure to achieve a MADRS score of <12
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1.Significant other psychiatric disorder which would interfere with trial assessments. Co-morbid generalized anxiety disorder (GAD) and panic will be permitted where MDD is considered the primary diagnosis .
•2.history of mania or bipolar disorder
•3.Known contraindication for the use of citalopram or escitalopram.
•4.Significant bleeding disorder
•5.Prominent suicidal ideation (score more than 4 in the MADRS suicidal thoughts” item)
•6.Alcohol or substance dependence in the past 6 months
•7.Major physical illness
•8.Significant liver or renal function abnormality
•9.Significant ECG abnormalities
•10.Pregnant or lactating females
•11.Inadequate contraception

发起方

CPS Research